Compare TGS & PTCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TGS | PTCT |
|---|---|---|
| Founded | 1992 | 1998 |
| Country | Argentina | United States |
| Employees | N/A | N/A |
| Industry | Natural Gas Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.7B | 5.5B |
| IPO Year | 2002 | 2006 |
| Metric | TGS | PTCT |
|---|---|---|
| Price | $29.65 | $66.98 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 17 |
| Target Price | $40.00 | ★ $79.41 |
| AVG Volume (30 Days) | 197.7K | ★ 1.0M |
| Earning Date | 01-01-0001 | 05-12-2026 |
| Dividend Yield | ★ 3.13% | N/A |
| EPS Growth | N/A | ★ 264.48 |
| EPS | N/A | ★ 7.78 |
| Revenue | N/A | ★ $264,734,000.00 |
| Revenue This Year | $50.92 | N/A |
| Revenue Next Year | N/A | $22.81 |
| P/E Ratio | $17.56 | ★ $8.72 |
| Revenue Growth | N/A | ★ 36.19 |
| 52 Week Low | $19.74 | $35.95 |
| 52 Week High | $34.10 | $87.50 |
| Indicator | TGS | PTCT |
|---|---|---|
| Relative Strength Index (RSI) | 47.30 | 29.79 |
| Support Level | $27.94 | $57.74 |
| Resistance Level | $32.56 | $68.44 |
| Average True Range (ATR) | 1.50 | 2.79 |
| MACD | -0.01 | -0.28 |
| Stochastic Oscillator | 49.56 | 19.53 |
Transportadora de Gas del Sur SA is a transporters of natural gas in Latin America. The company's operating segments include Natural Gas Transportation, Midstream, Telecommunications, Production and Commercialization Liquids, Other Services, and Telecommunications. It generates maximum revenue from the Production and Commercialization of the Liquids segment. Geographically, it derives the majority of its revenue from Argentina.
PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The company views its operations and manages its business in one operating segment: life science, which is focused on the discovery, development and commercialization of the company's clinically differentiated medicines that provide benefits to patients with rare disorders.